+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Namenda"

CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • April 2024
  • 898 Pages
  • Global
From
From
From
Alzheimer's Disease Market and Forecast Analysis 2034 - Product Thumbnail Image

Alzheimer's Disease Market and Forecast Analysis 2034

  • Drug Pipelines
  • February 2019
  • 300 Pages
  • Global
From
Analyzing the Global CNS Market 2018 - Product Thumbnail Image

Analyzing the Global CNS Market 2018

  • Report
  • April 2018
  • Global
From
Namenda - API Insight, 2022 - Product Thumbnail Image

Namenda - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Namenda- Drug Insight, 2019 - Product Thumbnail Image

Namenda- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
From
  • 11 Results (Page 1 of 1)
Loading Indicator

Namenda (memantine) is a drug used to treat moderate to severe Alzheimer's disease and other forms of dementia. It is a centrally acting NMDA receptor antagonist, which works by blocking the action of glutamate, a neurotransmitter that is thought to be involved in the development of Alzheimer's disease. Namenda is the only drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease. It is also used off-label to treat other forms of dementia, such as vascular dementia and Lewy body dementia. Namenda is part of a larger market of Central Nervous System (CNS) drugs, which includes drugs used to treat a variety of neurological conditions, such as depression, anxiety, epilepsy, and Parkinson's disease. CNS drugs are typically prescribed by neurologists and psychiatrists, and are often used in combination with other medications. Some companies in the Namenda market include Allergan, Lundbeck, and Otsuka Pharmaceuticals. Show Less Read more